The Significance of 18F-Fluorocholine-PET/CT as Localizing Imaging Technique in Patients with Primary Hyperparathyroidism and Negative Conventional Imaging

Stefan Fischli1†, Isabelle Suter-Widmer1*, Ba Tung Nguyen2, Werner Müller2, Jürg Metzger3, Klaus Strobel4, Hannes Grünig4 and Christoph Henzen1

1Division of Endocrinology, Diabetes and Clinical Nutrition, Luzerner Kantonsspital, Luzern, Switzerland, 2Division of Otorhinolaryngology, Head and Neck Surgery, Luzerner Kantonsspital, Luzern, Switzerland, 3Division of Visceral Surgery, Luzerner Kantonsspital, Luzern, Switzerland, 4Division of Nuclear Medicine/Radiology, Luzerner Kantonsspital, Luzern, Switzerland

Objective: The essential prerequisite for focused parathyroidectomy in patients with primary hyperparathyroidism (pHPT) is proper localization of all autonomic tissue. Sensitivity of conventional imaging modalities (ultrasound, 99mTc-sestamibi scintigraphy/SPECT/CT) is influenced by different factors (i.e., size/weight and position of autonomic tissue) and decreases in the presence of a multinodular goiter. Therefore, a considerable percentage of pHPT patients have negative or equivocal localization studies before surgery. The aim of this study is to evaluate the utility of FCH-PET/CT for preoperative localization in patients with pHPT and negative/equivocal 99mTc-sestamibi scintigraphy/SPECT/CT and/or ultrasound.

Methods and measurements: Between 2014 and 2017, a total of 39 patients with pHPT and negative/equivocal conventional imaging were referred for FCH-PET/CT. In the analysis, we included those (n = 23) who had surgery and a histopathologic workup of the lesions.

Results: 19 of 23 patients demonstrated no tracer uptake with 99mTc-sestamibi scintigraphy/SPECT/CT, 6 patients had an equivocal sonographic lesion, and multinodular goiter was present in 43% (10/23). In 21 of 23 patients, hyperfunctioning parathyroid tissue was identified correctly by FCH-PET/CT [21 true positives, 1 false negative, and 1 false positive; per-patient sensitivity 95.5% (95% confidence interval {CI}, 77.2–99.9)]. 29 lesions were resected [21 true positives, 3 false negatives, 1 false positive, and 4 true negatives; per-lesion sensitivity 87.5% (95% CI, 67.6–97.3)]. All patients were classified as having surgical success according to a decrease of intraoperative parathyroid hormone of ≥50% and normalization of postoperative serum calcium levels.
INTRODUCTION

Primary hyperparathyroidism (pHPT) is characterized by the autonomous secretion of parathyroid hormone (PTH) by one or more parathyroid glands. The most frequent cause of pHPT, occurring in 80–90% of patients, is a benign solitary parathyroid adenoma (1). However, multiple glandular disease occurs in 10–20% of patients, either as a double adenoma or as a multiple glandular hyperplasia (1, 2). The latter typically occurs in familial forms of pHPT (e.g., MEN 1/2 or CDKN1B mutations) or in patients treated with lithium. An additional fifth parathyroid gland is found in 6–15% of patients (3, 4). Due to migration during embryological development, the anatomical localizations of parathyroid glands are highly variable. Ectopic localizations are found in ≤20% of patients in an autopsy series (5), with an even higher prevalence (≤50%) in patients with persistent or recurrent pHPT after surgery (6, 7).

Surgery is the only definitive cure for pHPT and is indicated in all symptomatic patients and in a defined subgroup of “asymptomatic” patients (8). The goals of parathyroid surgery are to remove all hyperfunctioning tissue and to preserve normal parathyroid glands to prevent postoperative hypoparathyroidism. In the past, the standard surgical approach included bilateral cervical exploration regardless of preoperative imaging studies. Minimally invasive or focused approaches have currently gained more acceptance as safe and effective alternatives (9–11), with the advantages of a shorter duration of surgery, a reduction of tissue damage (7), and a lower complication rate (12–15). The essential prerequisite for focused parathyroidectomy is proper localization of all autonomic tissue, including detection of ectopic and super numerous parathyroid lesions.

The most commonly used imaging modalities for this purpose are ultrasounds of the neck and parathyroid scintigraphy with 99mTc-sestamibi (15, 16). Cervical ultrasound has a reported sensitivity ranging from 64 to 89% (17, 18); however, the detection rate is operator dependent and is lower in patients with multiple glandular disease and with multinodular goiters (2, 19). In addition, sonographic assessment of ectopic lesions is limited to retrotracheal or retroesophageal localizations, or even impossible in the case of an intrathoracic adenoma.

The technique of 99mTc-sestamibi scintigraphy, often in combination with SPECT/CT, is considered the reference method for preoperative parathyroid imaging, with a sensitivity of 70–88% (2, 17, 18). As in ultrasound, the sensitivity is reduced in patients with multiglandular disease and multinodular goiter, and the diagnostic accuracy depends on the size and weight of the parathyroid gland (19, 20). However, even in the presence of a single uptaking focus in scintigraphy, multiglandular disease cannot be precluded (21). Even combined imaging with ultrasound and 99mTc-sestamibi scintigraphy/SPECT/CT leaves a considerable percentage of pHPT patients with negative or equivocal localization studies before surgery, in which cases, successful parathyroidectomy depends solely on the expertise of the surgeon.

Recent patient level studies have shown good accuracy and equal or even superior detection using 18F-fluorocholine-PET/CT (FCH-PET/CT) compared to commonly used imaging using 99mTc-sestamibi scintigraphy, ultrasound, and four-dimensional computed tomography (21–24). In this study, we therefore evaluated the sensitivity and specificity of FCH-PET/CT for preoperative localization in patients with pHPT and negative or equivocal 99mTc-sestamibi scintigraphy and/or ultrasound.

SUBJECTS AND METHODS

This was a retrospective cohort study from January 2014 to March 2017 that included patients with pHPT older than 18 years who were candidates for focused parathyroidectomy, as defined by the current guidelines (8). All patients had negative or equivocal localization studies with 99mTc-sestamibi scintigraphy/SPECT/CT and were offered additional imaging with FCH-PET/CT. Written consent was obtained from all participants after they were informed that FCH-PET/CT was an authorized diagnostic imaging procedure for indications other than parathyroid disease. PTH was measured intraoperatively (iOPTH), and serum calcium was determined on the first postoperative day. A decrease of ≥50% of iOPTH and normalized serum calcium postoperatively were defined as surgical success. A total of 39 patients with pHPT were referred for FCH-PET/CT; 23 of these patients eventually had parathyroidectomy and a histopathological workup of the lesions and were included in the study (Figure 1).

18F-Fluorocholine-PET/CT

After intravenous injection of 18F-fluorocholine (median applied activity, 160 MBq; IQR, 180–149), with an uptake time of 45 min, images were obtained using a PET/CT (Discovery 600; GE Healthcare, USA). First, a contrast-enhanced CT was acquired from the base of the skull to the diaphragm. PET images were then obtained using a 3-min acquisition time per bed position. Images were sent to a dedicated workstation (AW, GE Healthcare) and the PET/CT images were analyzed by a physician who was board certified in radiology and nuclear medicine with 12 years of experience reading of PET/CT images. Focal lesions with significant tracer uptake on PET images and corresponding nodular lesions in CT, found in typical locations for orthotopic...
or heterotopic parathyroid tissues, were rated as positive PET/CT studies.

**Surgical Methods**

23 included patients with pHPT underwent surgery in general anesthesia in our hospital. The surgical procedure was an open minimal invasive parathyroidectomy with recurrent laryngeal nerve monitoring in 21 patients. In two patients, ectopic/mediastinal adenoma resection was performed by a thoracoscopic approach. Depending on the diagnostic result of the preoperative FCH-PET/CT, unilateral or a bilateral neck exploration was done. In case of coexisting with a multinodular goiter, a thyroidectomy was also performed. The total intraoperative number of lesions found, and their location were recorded. To confirm the success of the surgical procedure resection, specimens were cut and frozen to determine the histological subtype: normal or hyperfunctioning parathyroid tissue. After introduction of general anesthesia and 7 min after surgical removal of the last enlarged tissue, PTH was determined to confirm its decrease. The procedure was defined successful if there was a decrease in the serum PTH of more than 50% from the baseline. Regular control of serum calcium and PTH was performed after surgery to document the success of the parathyroidectomy and to determine clinically relevant hypocalcemia symptoms. No operative complications in all patients were observed. The histopathological analysis served as the gold standard for comparison with the preoperative imaging results.

**Performance Analysis**

FCH-PET/CT imaging results were compared with the intraoperative situs and the histopathological examination as the gold standard for the diagnosis of hyperfunctioning parathyroid tissue. The results of the FCH-PET/CT were classified as (a) true positive: the regional tracer uptake correlated with the histological results of hyperfunctioning parathyroid tissue, (b) false positive: a regional tracer uptake with histology other than hyperfunctioning parathyroid tissue, (c) false negative: an absent regional tracer uptake with a histology of hyperfunctioning parathyroid tissue, and (d) true negative: an absent regional tracer uptake and histological findings of normal parathyroid tissue.

**Statistical Analysis**

Based on the performance analysis (cf. above), sensitivities were calculated on a per-patient and a per-lesion basis using the quotient of true positive/true positive + true negative. 95% confidence interval (CI) for sensitivity is calculated by the Clopper–Pearson method. If not stated otherwise, values are expressed as median and IQR (Q3–Q1).

**RESULTS**

The baseline characteristics of the patients are shown in Table 1. A total of 23 patients (18 females and 5 males) were referred for surgery, 4 of them needed repeated procedures. Four of the 10 patients with goiters had hemithyroidectomy, and 2 patients had total thyroidectomy. There was no uptake using 99mTc-sestamibi scintigraphy/SPECT/CT in 19 patients and an undefined uptake in 4 patients. Six patients had equivocal lesions in the sono graphic examination of the cervical region, and all other ultrasound examinations were negative. In 10 of 23 (43%) patients, multinodular goiters were present, and all patients had a normal thyroid function.

FCH-PET/CT showed 22 lesions, and 1 patient had negative imaging with FCH-PET/CT. A total of 29 parathyroid lesions were resected, and histopathological examinations revealed
24 instances of overfunctioning parathyroid tissues, with parathyroid glands with a normal histology. All patients were classified as a surgical success based on the decrease of ioPTH and normalization of postoperative serum calcium levels. The postoperative course was uneventful in all patients, with no complications from the surgery. The details of the imaging and the intraoperative and the histopathological findings are listed in Table 2.

In 21 of 23 patients, hyperfunctioning parathyroid tissue (adenoma/hyperplasia) was correctly localized by FCH-PET/CT (21 true positive, 1 false negative, and 1 false positive). The patient (patient 14) with false-negative FCH-PET/CT had multiglandular disease. This translates into a per-patient sensitivity of 95.5% (95% CI, 77.2–99.9). On a per-lesion basis (29 lesions resected), there were 21 true positives, 3 false negatives, 1 false positive, and 4 true negatives, which accounted for a lesion-based sensitivity of 87.5% (95% CI, 67.6–97.3). Nine patients had equivocal/doubtful findings in the ultrasound and/or 99mTc-sestamibi scintigraphy/SPECT/CT. In 8 of these 9 patients, FCH-PET/CT provided the correct diagnosis.

Despite the high prevalence of multinodular goiters, the diagnostic accuracy of the FCH-PET/CT was excellent, especially for thyroid nodules that did not lead to false-positive findings. In one case (patient 13), the thyroid gland showed diffusely enhanced uptake, but the adenoma was clearly circumscribed. In another case, there was focal uptake in the liver, but no other foci were found in males (i.e., prostate) or females (i.e., breast).

TABLE 1 | Characteristics of the patients.

| Parameter                      | Value* |
|-------------------------------|--------|
| Age (years)                   | 61.9 (41–83) |
| Serum calcium preoperative (mmol/L) | 2.69 (2.62–2.60) |
| PTH preoperative (pg/mL)      | 13.7 (220–104) |
| Serum calcium postoperative (mmol/L) | 2.19 (2.32–2.07) |
| PTH postoperative (pg/mL)     | 35 (49–23) |
| ioPTH decrease (%)            | 79 (85–64) |
| Weight of adenoma/hyperplastic gland (g)b | 0.95 (1.8–0.38) |

*All values are median values (IQR), except for age: mean (range).

- **TABLE 2 | Laboratory findings, imaging, and histological results.**

| Subj. Nr. | Ca preop. (mmol/L) | Ca. postop. (mmol/L) | PTH intraop. before surgery (pg/mL) | PTH intraop. after surgery (pg/mL) | PTH first day after surgery (pg/mL) | Preop. US | Preop. sestamibi | Preop. 18F-FCH | Nodular goiter | Resected lesions | Histology |
|----------|--------------------|----------------------|------------------------------------|------------------------------------|------------------------------------|----------|----------------|----------------|---------------|----------------|----------|
| 1        | 2.76               | 2.13                 | 120                                | 20                                 | 48                                 | –        | –              | –              | PSR           | –              | P3R Ad   |
| 2        | 2.72               | 2.41                 | 112                                | 23                                 | 20                                 | P?4R     | –              | –              | PSR/PSR       | –              | P3R/P4R  |
| 3        | 2.60               | 2.15                 | 220                                | 47                                 | 73                                 | –        | –              | –              | P4L           | Yes            | P3L/P4L   |
| 4        | 2.60               | 2.36                 | 89                                 | 36                                 | 42                                 | –        | –              | –              | PSR           | Yes            | PSR HT   |
| 5        | 2.75               | 2.17                 | 127                                | 33                                 | 26                                 | –        | –              | –              | P4L           | –              | P4L HT   |
| 6        | 3.07               | 2.58                 | 164                                | 87                                 | 61                                 | –        | –              | –              | PSR           | Yes            | P3R HT   |
| 7        | 2.67               | 2.38                 | 100                                | 15                                 | 5                                  | –        | –              | –              | P3L           | Yes            | P4L HT   |
| 8        | 2.76               | 2.37                 | 423                                | 19                                 | 19                                 | –        | –              | –              | P4R           | Yes            | P4R HT   |
| 9        | 2.65               | 2.25                 | 128                                | 22                                 | 50                                 | –        | –              | –              | P4L           | Yes            | P4R HT   |
| 10       | 2.65               | 2.27                 | 148                                | 28                                 | 49                                 | –        | –              | –              | P3R/PSR       | Yes            | P3R HT   |
| 11       | 2.77               | 2.25                 | 177                                | 51                                 | 9                                  | –        | –              | –              | P4R           | Yes            | Hemithy R* |
| 12       | 2.61               | 2.23                 | 84                                 | 18                                 | 14                                 | –        | –              | –              | P4L           | Yes            | P3R/PSR  |
| 13       | 2.67               | 2.30                 | 395                                | 95                                 | 6                                  | –        | –              | –              | P3L/PSR       | Yes            | P3L HT   |
| 14       | 2.60               | 2.31                 | 104                                | 25                                 | 13                                 | –        | –              | –              | P3R           | Yes            | P3L HT   |
| 15       | 2.75               | 2.16                 | 119                                | 17                                 | 13                                 | –        | –              | –              | Me/Thy        | Yes            | P3L HT   |
| 16       | 2.64               | 2.2                  | 137                                | 23                                 | 34                                 | –        | –              | –              | ?PSR/P3R      | Yes            | P3L HT   |
| 17       | 2.51               | 2.2                  | 68                                 | 33.8                               | 47.8                               | –        | –              | –              | PSL/PSL       | Yes            | P3L/P4L  |
| 18       | 2.5                | 2.18                 | 157                                | 72                                 | 42                                 | –        | –              | –              | P3R           | Yes            | P3R HT   |
| 19       | 3.03               | 2.45                 | 473                                | 104                                | 21                                 | –        | –              | –              | P3L/PSL       | Yes            | P3L HT   |
| 20       | 3.06               | 2.39                 | 129                                | 24                                 | 16                                 | –        | –              | –              | P3L           | Yes            | P3L HT   |
| 21       | 2.55               | 2.12                 | 100                                | 12.2                               | 16.5                               | –        | –              | –              | P3L           | Yes            | P3L HT   |
| 22       | 2.73               | 1.66                 | 203                                | 30.5                               | 17.7                               | –        | –              | –              | P3L/P4L       | Yes            | P3R HT   |
| 23       | 2.55               | 2.19                 | 96                                 | 35                                 | 51                                 | –        | –              | –              | P3L           | Yes            | P3L HT   |

*Intrathyroidal adenoma; ?, equivocal/doubtful; –, no localization possible/absent.
P3, inferior parathyroid gland; P4, superior parathyroid gland; R, right; L, left; No, normal parathyroid tissue; Hemithy, hemithyroidectomy; Me, mediastinal; HT, hyperfunctioning tissue; Thy, thymus.

**DISCUSSION**

We report a retrospective cohort study of patients with pHPT and negative conventional imaging studies, who underwent 18F-fluorocholine-PET/CT as an additional imaging technique for localization.

Our results showed the excellent ability of FCH-PET/CT to localize hyperfunctioning parathyroid tissue in patients with pHPT and negative or equivocal sestamibi/ultrasound findings (representative case: Figure 2). We confirmed the superior diagnostic ability of this newer functional imaging technique as reported in other studies (22, 23, 25). Compared to other studies (22, 23, 25), our study cohort was uniform, so the resulting localization accuracy may be representative of patients with sporadic pHPT and negative conventional imaging.
Our study cohort was characterized by a high prevalence of coexisting multinodular goiters or thyroid nodules (43%), which may be at least partially responsible for the high rate of negative imaging with $^{99m}$Tc-sestamibi scintigraphy/SPECT/CT and/or ultrasound. Previous studies have reported that the sensitivity of $^{99m}$Tc-sestamibi scintigraphy and/or ultrasound decreases in the presence of thyroid nodules or a multinodular goiter (26–29). However, in our patients with goiters, the FCH-PET/CT localized the lesions correctly within the “classical” positions.

The one patient with false-negative FCH-PET/CT followed by successful surgery had a multiglandular disease. Three excluded patients who had unsuccessful prior surgery were also negative using FCH-PET/CT (one patient had a known D418D polymorphism and two had MEN 1). This suggests that parathyroid multigland involvement in patients with pHPT may reduce the sensitivity and specificity of FCH-PET/CT, so further studies are needed using FCH-PET/CT for patients with pHPT because of a multigland disease, such as MEN 1/2 and D418D polymorphism.

Approximately (20–30%) of patients with pHPT and negative conventional imaging before parathyroidectomy are commonly found in daily clinical practice (30–32). When a focused parathyroidectomy is planned, some clinicians select additional diagnoses (31). Conventional MRI and CT have low detection rates and are generally not recommended (18). Four-dimensional CT provides an improved sensitivity of approximately 88% (33, 34), but results in a much higher radiation dose to the thyroid bed (35, 36). Furthermore, selective venous sampling is cumbersome and reserved for special situations (18).

Compared to scintigraphy and SPECT/CT, PET/CT offers better spatial resolution and better lesion to background ratios. In addition, PET can be easily combined with a diagnostic contrast-enhanced CT to provide the surgeon with important anatomical information regarding the localization of the parathyroid adenoma in relationship to other important structures such as the trachea, vessels, and the esophagus. With optimization of the PET/CT protocol, the radiation dose of FCH-PET/CT is comparable to SPECT/CT, using approximately 8 mSv (37).

The limitations of this study are threefold; it is a retrospective analysis, the sample size was small, and we had to exclude several patients from surgery. There was also a selection bias toward patients with negative/equivocal imaging.

In conclusion, our study showed that for patients with pHPT and negative/equivocal imaging with $^{99m}$Tc-sestamibi scintigraphy/ultrasound, FCH-PET/CT provides an excellent sensitivity of >90% per-patient and of >87% per lesion-based level. Furthermore, the diagnostic accuracy of FCH-PET/CT remains unchanged in the presence of thyroid nodules or multinodular

---

**FIGURE 2** A representative case of a patient with multinodular goiter and negative conventional imaging. Images of an 82-year-old patient (patient number 9). Ultrasound (A) showing a bilateral multinodular goiter and no visible parathyroid adenoma. $^{99m}$Tc-sestamibi SPECT/CT (B,C) without detection of a parathyroid adenoma. FCH-PET/CT (D–F) with clear visualization of a small parathyroid retrotracheal adenoma at the upper right pole.
goiters. However, larger cohorts are needed in future trials to confirm the findings of our study.

ETHICS STATEMENT

The study conformed to the declaration of Helsinki and was approved by the local ethics committee (approval number: EKNZ-2017-00021).

AUTHOR CONTRIBUTIONS

Drafting of the study and the manuscript was carried out by all authors. Acquisition, analysis, and interpretation of the data were carried out by BN, WM, and JM (surgical part); KS and HG (hormones). The study was approved by the local ethics committee (approval number: T1007/17). All authors confirm the findings of our study.

REFERENCES

1. Kaplan EL, Yashiro T, Salti G. Primary hyperparathyroidism in the 1990s. Choice of surgical procedures for this disease. *Ann Surg* (1992) 215:300–17. doi:10.1097/00000658-199204000-00002
2. Ruda JM, Hollemeek CS, Stack BC. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. *Otolaryngol Head Neck Surg* (2005) 132:359–72. doi:10.1016/j.otohns.2004.10.005
3. Akerström G, Malmaeus J, Bergström R. Surgical anatomy of human parathyroid glands. *Surgery* (1994) 95:14–21.
4. Baloch ZW, LiVolsi VA. Pathology of the parathyroid glands in hyperparathyroidism. *Semin Diagn Pathol* (2013) 30:165–77. doi:10.1053/j.semdp.2013.06.003
5. Gilmour JR. The embryology of the parathyroid glands, the thymus and certain associated rudiments. *J Pathol Bacterial* (1937) 45:507–22. doi:10.1002/j.1464-5066.1937.tb12139.x
6. Shen W, Düren M, Morita E, Higgins C, Duh QY, Spirestein AE, et al. Reoperation for persistent or recurrent primary hyperparathyroidism. *Arch Surg* (1996) 131:861–7; discussion 867–9. doi:10.1001/archsurg.1996.01430200071013
7. Udelsman R, Åkerström G, Biagini C, Duh Q-Y, Donovan P, Niederle B, et al. The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. *J Clin Endocrinal Metab* (2014) 99:3595–606. doi:10.1212/jc.0000000000000055
8. Marocci C, Bollersejj L, Khan AA, Shoback DM. Medical management of primary hyperparathyroidism: proceedings of the Fourth International Workshop on the management of asymptomatic primary hyperparathyroidism. *J Clin Endocrinol Metab* (2014) 99:3607–18. doi:10.1212/jc.0000000000000068
9. Udelsman R, Lin Z, Donovan P. The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism. *Ann Surg* (2011) 253:585–91. doi:10.1097/SLA.0b013e318208fed9
10. Van Udelsman B, Udelsman R. Surgery in primary hyperparathyroidism: extensive personal experience. *J Clin Densitom* (2013) 16:54–9. doi:10.1016/j.jocd.2012.11.007
11. Ledder SB, Donovan P, Acton LM, Warner HL, Carling T, Alian AA, et al. Laryngeal physiology and voice acoustics are maintained after minimally invasive parathyroidectomy. *Ann Surg* (2013) 257:968–70. doi:10.1097/SLA.0b013e3182883ec6
12. Lew JJ, Solorzano CC. Surgical management of primary hyperparathyroidism: state of the art. *Surg Clin North Am* (2009) 89:1205–25. doi:10.1016/j.suc.2009.06.014
13. Irvin GL, Carneiro DM, Solorzano CC. Progress in the operative management of sporadic primary hyperparathyroidism over 34 years. *Ann Surg* (2004) 239:704–8; discussion 708–11. doi:10.1097/01.sl.a.0000124448.49794.74
14. Norman J, Chheda H, Farrell C. Minimally invasive parathyroidectomy for primary hyperparathyroidism: decreasing operative time and potential complications while improving cosmetic results. *Am Surg* (1998) 64:391–5; discussion 395–6.
15. Sackett WR, Barralough B, Reeve TS, Delbridge LW. Worldwide trends in the surgical treatment of primary hyperparathyroidism in the era of minimally invasive parathyroidectomy. *Arch Surg* (2002) 137:1055–9. doi:10.1001/archsurg.137.9.1055
16. Liddy S, Worsley D, Torreggiani W, Feeney J. Preoperative imaging in primary hyperparathyroidism: literature review and recommendations. *Can Assoc Radiol J* (2017) 68:47–55. doi:10.1016/j.carj.2016.07.004
17. Cheung K, Wang TS, FarrokhYar F, Roman SA, Sosa JA. A meta-analysis of 13 preoperative localization techniques for patients with primary hyperparathyroidism. *Ann Surg Oncol* (2012) 19:577–83. doi:10.1245/s10434-011-1870-5
18. Mihai R, Simon D, Hellman P. Imaging for primary hyperparathyroidism – an evidence-based analysis. *Langenbecks Arch Surg* (2009) 394:765–84. doi:10.1007/s00423-009-0534-4
19. Prager G, Czerny O, Ofthuoglu S, Kurutan A, Passler C, Kacizrek K, et al. Impact of localization studies on feasibility of minimally invasive parathyroidectomy in an endemic goiter region. *J Am Coll Surg* (2003) 196:541–8. doi:10.1016/s1072-7515(02)01897-5
20. Wachtel H, Bartlett EE, Kelz RR, Cerullo I, Karakousis GC, Fraker DL. Primary hyperparathyroidism with negative imaging: a significant clinical problem. *Ann Surg* (2014) 260:474–80; discussion 480–2. doi:10.1097/SLA.0000000000000875
21. Yip L, Pryma DA, Yim JH, Virji MA, Carty SE, Ogilvie JB. Can a lightbulb septambi SPECT accurately predict single-gland disease in sporadic primary hyperparathyroidism? *World J Surg* (2008) 32:784–92; discussion 793–4. doi:10.1007/s00268-008-9532-x
22. Kluijfhout WP, Vorselaars WMC, Vriens MR, Borrel Rinks IHM, Valk GD, de Keijzer B. Enabling minimal invasive parathyroidectomy for patients with primary hyperparathyroidism using Tc-99m-sestambi SPECT-CT, ultrasound and first results of 18F-fluorocholine PET-CT. *Eur J Radiol* (2015) 84:1745–51. doi:10.1016/j.ejrad.2015.05.024
23. Michaud I, Burgess A, Huchet V, Lefèvre M, Tassign T, Ohnorna J, et al. Is 18F-fluorocholine-positron emission tomography/computed tomography a new imaging tool for detecting hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism? *J Clin Endocrinol Metab* (2014) 99:4531–6. doi:10.1212/jc.0000000000000875
24. Taywade SK, Dantine NA, Behera A, Devasenathipathy K, Bal C, Tripathi M, et al. Comparison of 18F-fluorocholine positron emission tomographycomputed tomography and four-dimensional computed tomography in the preoperative localization of parathyroid adenomas-initial results. *Indian J Endocrinol Metab* (2017) 21:399–403. doi:10.4103/ijem.IJEM_53_16
25. Lezaic I, Rep S, Sever MJ, Kocjan T, Hoevear M, Fettich J. 18F-Fluorocholine PET/CT for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism: a pilot study. *Eur J Nucl Med Mol Imaging* (2014) 41:2083–9. doi:10.1007/s00259-014-2837-0
26. Erbil Y, Barbaros U, Yanik BT, Salmaslioğlu A, Tunaci M, Ashafe I, et al. Impact of gland morphology and concomitant thyroid nodules on
preoperative localization of parathyroid adenomas. 

27. Barbaros U, Erbil Y, Salmashoglu A, Issever H, Aral F, Tunaci M, et al. The characteristics of concomitant thyroid nodules cause false-positive ultrasonography results in primary hyperparathyroidism. *Am J Otolaryngol* (2009) 30:239–43. doi:10.1016/j.amjoto.2008.06.007

28. Sukan A, Reyhan M, Aydin M, Yaper AF, Sert Y, Canpolat T, et al. Preoperative evaluation of hyperparathyroidism: the role of dual-phase parathyroid scintigraphy and ultrasound imaging. *Ann Nucl Med* (2008) 22:123–31. doi:10.1007/s12149-007-0086-2

29. Barczynski M, Golkowski F, Konturek A, Buziak-Bereza M, Cichon S, Hubalewska-Dydejczyk A, et al. Technetium-99m-sestamibi subtraction scintigraphy vs. ultrasonography combined with a rapid parathyroid hormone assay in parathyroid aspirates in preoperative localization of parathyroid adenomas and in directing surgical approach. *Clin Endocrinol (Oxf)* (2006) 65:106–13. doi:10.1111/j.1365-2265.2006.02556.x

30. Mihai R, Gleson F, Buley ID, Roskell DE, Sadler GP. Negative imaging studies for primary hyperparathyroidism are unavoidable: correlation of sestamibi and high-resolution ultrasound scanning with histological analysis in 150 patients. *World J Surg* (2006) 30:697–704. doi:10.1007/s00268-005-0338-9

31. Lal A, Chen H. The negative sestamibi scan: is a minimally invasive parathyroidectomy still possible? *Ann Surg Oncol* (2007) 14:2363–6. doi:10.1245/s10434-007-9451-3

32. Chiu B, Sturgeon C, Angelos P. What is the link between nonlocalizing sestamibi scans, multigland disease, and persistent hypercalcemia? A study of 401 consecutive patients undergoing parathyroidectomy. *Surgery* (2006) 140:418–22. doi:10.1016/j.surg.2006.03.021

33. Rodgers SE, Hunter GJ, Hamberg LM, Shellingherdout D, Doherty DB, Ayers GD, et al. Improved preoperative planning for directed parathyroidectomy with 4-dimensional computed tomography. *Surgery* (2006) 140:932–40; discussion 940–1. doi:10.1016/j.surg.2006.07.028

34. Mortensen MM, Evans DB, Lee JE, Hanter GJ, Shellingherdout D, Vu T, et al. Parathyroid exploration in the reoperative neck: improved preoperative localization with 4D-computed tomography. *J Am Coll Surg* (2008) 206:888–95; discussion 895–6. doi:10.1016/j.jamcollsurg.2007.12.044

35. Madorin CA, Owen R, Cookley B, Lowe H, Nam K-H, Weber K, et al. Comparison of radiation exposure and cost between dynamic computed tomography and sestamibi scintigraphy for preoperative localization of parathyroid lesions. *JAMA Surg* (2013) 148:500–3. doi:10.1001/jamasurg.2013.57

36. Mahajan A, Starker LF, Ghiha M, Udelsman R, Brink JA, Carling T. Parathyroid four-dimensional computed tomography: evaluation of radiation dose exposure during preoperative localization of parathyroid tumors in primary hyperparathyroidism. *World J Surg* (2012) 36:1335–9. doi:10.1007/s00268-012-1365-3

37. DeGrado TR, Reiman RE, Price DT, Wang S, Coleman RE. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. *J Nucl Med* (2002) 43:92–6.

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.